Apolipoprotein E genotype does not influence the progression of multiple sclerosis

[1]  B. Weinshenker,et al.  Natural history of multiple sclerosis. , 2005, Neurologic clinics.

[2]  J. Haines,et al.  Multiple susceptibility loci for multiple sclerosis. , 2002, Human molecular genetics.

[3]  P. Sørensen,et al.  Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E) , 2002, Multiple sclerosis.

[4]  P. Goodfellow,et al.  A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility. , 2002, Brain : a journal of neurology.

[5]  L. Lannfelt,et al.  APOE genotypes and disease severity in multiple sclerosis , 2002, Multiple sclerosis.

[6]  J. Haines,et al.  Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. , 2002, American journal of human genetics.

[7]  K. Becker.  APOE genotype is a major predictor of long-term progression of disability in MS , 2001, Neurology.

[8]  C. Enzinger,et al.  Apolipoprotein E ε4 is associated with rapid progression of multiple sclerosis , 2001, Neurology.

[9]  D. Clayton,et al.  A genome screen for multiple sclerosis in Italian families , 2001, Genes and Immunity.

[10]  S. Sorbi,et al.  Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis , 2000, Neuroscience Letters.

[11]  O. Paulson,et al.  Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate , 2000, Multiple sclerosis.

[12]  R. Strange,et al.  Polymorphisms of apolipoprotein E; outcome and susceptibility in multiple sclerosis , 2000, Multiple sclerosis.

[13]  F. Panza,et al.  Decreased frequency of apolipoprotein E ε4 allele from Northern to Southern Europe in Alzheimer's disease patients and centenarians , 1999, Neuroscience Letters.

[14]  A. Quattrone,et al.  APOE and risk of cognitive impairment in multiple sclerosis , 1999, Acta neurologica Scandinavica.

[15]  G. Comi,et al.  APOE ε2-4 and -491 polymorphisms are not associated with MS , 1999, Neurology.

[16]  N. Evangelou,et al.  Association of the APOE ε4 allele with disease activity in multiple sclerosis , 1999, Journal of neurology, neurosurgery, and psychiatry.

[17]  R. Corbo,et al.  Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele? , 1999, Annals of human genetics.

[18]  M. Gold,et al.  The −491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism , 1998, Neuroscience Letters.

[19]  D. Rubinsztein,et al.  Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease. , 1994, Molecular and cellular probes.

[20]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[21]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[22]  S. Poser,et al.  HLA-antigens and the prognosis of multiple sclerosis , 2004, Journal of Neurology.

[23]  G. Comi,et al.  APOE epsilon2-4 and -491 polymorphisms are not associated with MS. , 1999, Neurology.